JP2008189679A5 - - Google Patents

Download PDF

Info

Publication number
JP2008189679A5
JP2008189679A5 JP2008066772A JP2008066772A JP2008189679A5 JP 2008189679 A5 JP2008189679 A5 JP 2008189679A5 JP 2008066772 A JP2008066772 A JP 2008066772A JP 2008066772 A JP2008066772 A JP 2008066772A JP 2008189679 A5 JP2008189679 A5 JP 2008189679A5
Authority
JP
Japan
Prior art keywords
mitiglinide
hydrate
acceptable salt
pharmacologically acceptable
voglibose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008066772A
Other languages
English (en)
Japanese (ja)
Other versions
JP5117230B2 (ja
JP2008189679A (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2008066772A priority Critical patent/JP5117230B2/ja
Priority claimed from JP2008066772A external-priority patent/JP5117230B2/ja
Publication of JP2008189679A publication Critical patent/JP2008189679A/ja
Publication of JP2008189679A5 publication Critical patent/JP2008189679A5/ja
Application granted granted Critical
Publication of JP5117230B2 publication Critical patent/JP5117230B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2008066772A 2005-04-20 2008-03-14 2型糖尿病治療用の併用医薬 Expired - Lifetime JP5117230B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2008066772A JP5117230B2 (ja) 2005-04-20 2008-03-14 2型糖尿病治療用の併用医薬

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2005121862 2005-04-20
JP2005121862 2005-04-20
JP2005166314 2005-06-07
JP2005166314 2005-06-07
JP2008066772A JP5117230B2 (ja) 2005-04-20 2008-03-14 2型糖尿病治療用の併用医薬

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2007514602A Division JP4230524B2 (ja) 2005-04-20 2006-04-18 2型糖尿病治療用の併用医薬

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012000738A Division JP2012092140A (ja) 2005-04-20 2012-01-05 2型糖尿病治療用の併用医薬

Publications (3)

Publication Number Publication Date
JP2008189679A JP2008189679A (ja) 2008-08-21
JP2008189679A5 true JP2008189679A5 (enExample) 2012-03-15
JP5117230B2 JP5117230B2 (ja) 2013-01-16

Family

ID=37214736

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2007514602A Expired - Lifetime JP4230524B2 (ja) 2005-04-20 2006-04-18 2型糖尿病治療用の併用医薬
JP2008066772A Expired - Lifetime JP5117230B2 (ja) 2005-04-20 2008-03-14 2型糖尿病治療用の併用医薬
JP2012000738A Pending JP2012092140A (ja) 2005-04-20 2012-01-05 2型糖尿病治療用の併用医薬

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2007514602A Expired - Lifetime JP4230524B2 (ja) 2005-04-20 2006-04-18 2型糖尿病治療用の併用医薬

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012000738A Pending JP2012092140A (ja) 2005-04-20 2012-01-05 2型糖尿病治療用の併用医薬

Country Status (7)

Country Link
US (1) US7888382B2 (enExample)
EP (1) EP1872781A4 (enExample)
JP (3) JP4230524B2 (enExample)
KR (1) KR101380813B1 (enExample)
CN (1) CN101198326B (enExample)
CA (1) CA2605302A1 (enExample)
WO (1) WO2006115115A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006115115A1 (ja) * 2005-04-20 2006-11-02 Kissei Pharmaceutical Co., Ltd. 2型糖尿病治療用の併用医薬
CN105296620B (zh) 2015-10-26 2019-01-15 上海市内分泌代谢病研究所 肠道宏基因组特征作为2型糖尿病阿卡波糖疗效筛选标志
JP7680822B2 (ja) * 2017-08-08 2025-05-21 日本ケミファ株式会社 糖尿病治療剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030040490A1 (en) * 2000-02-24 2003-02-27 Yasuo Sugiyama Drugs containing combined active ingredients
JP4917712B2 (ja) * 2000-02-24 2012-04-18 武田薬品工業株式会社 併用医薬
US6830759B2 (en) * 2002-06-28 2004-12-14 Ajinomoto Co., Inc. Antidiabetic preparation for oral administration
EP1532979A4 (en) 2002-06-28 2008-01-16 Kissei Pharmaceutical DRUG COMPOSITION FOR REGULATING GLYCEMIA
US20050020654A1 (en) * 2003-03-15 2005-01-27 Pershadsingh Harrihar A. Novel PPAR agonists, pharmaceutical compositions and uses thereof
AU2004261660A1 (en) * 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted fused heterocyclic C-glycosides
US20050197376A1 (en) * 2004-03-02 2005-09-08 Fujisawa Pharmaceutical Co. Ltd. Concomitant drugs
WO2006115115A1 (ja) * 2005-04-20 2006-11-02 Kissei Pharmaceutical Co., Ltd. 2型糖尿病治療用の併用医薬
CN101325959A (zh) * 2005-09-14 2008-12-17 伊利舍医药品公司 用于受控碳水化合物消化的联合疗法

Similar Documents

Publication Publication Date Title
JP2014518860A5 (enExample)
FI2981255T3 (fi) Empagliflotsiinin terapeuttiset käytöt
JP2012512907A5 (enExample)
FI3716979T3 (fi) 4-pyrimidiinisulfamidijohdannaisen ja SGLT-2-inhibiittorin yhdistelmä endoteliiniin liittyvien sairauksien hoitamiseksi
WO2006105501A3 (en) Control of blood glucose in diabetes treatment using pulmonarily administered insulin in combination with basal insulin
JP2010529118A5 (enExample)
FI2396005T3 (fi) Sglt2:n estäjä verensokeritasapainon parantamiseksi
EA021275B9 (ru) Гетероциклические соединения, содержащая их фармацевтическая композиция и их применение для лечения pask-опосредованного заболевания
MX2010004450A (es) Derivados heterociclo biciclicos y su uso como moduladores de la actividad de gpr119.
NO20084321L (no) Triazolderivat eller salt derav
JP2011500690A5 (enExample)
JP2019089796A5 (enExample)
JP2012517449A5 (enExample)
WO2012019188A3 (en) Methods and compositions for the inhibition of fructokinase
JP2018509419A5 (enExample)
MX2009011900A (es) Curacion de herida diabetica.
UA84282C2 (ru) Применение телмисартана и аторвастатина для лечения сахарного диабета типа іі и фармацевтическая композиция
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
JP2011519873A5 (enExample)
JP2008266291A5 (enExample)
JP2009516719A5 (enExample)
MXPA05007559A (es) Combinacion farmaceutica para la prevencion o la terapia de enfermedades cardiovasculares, cardiopulmonares, pulmonares o renales.
JP2013507383A5 (enExample)
UA108980C2 (en) APPLICATION OF DONEDARONE FOR THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATIONS
JP2011500650A5 (enExample)